- Home
- TYRA vs WIW Comparison
TYRA vs WIW Comparison
Compare TYRA & WIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- WIW
- Stock Information
- Founded
- TYRA 2018
- WIW 2004
- Country
- TYRA United States
- WIW United States
- Employees
- TYRA N/A
- WIW N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- WIW Finance Companies
- Sector
- TYRA Health Care
- WIW Finance
- Exchange
- TYRA Nasdaq
- WIW Nasdaq
- Market Cap
- TYRA 576.6M
- WIW 521.9M
- IPO Year
- TYRA 2021
- WIW N/A
- Fundamental
- Price
- TYRA $9.23
- WIW $8.73
- Analyst Decision
- TYRA Strong Buy
- WIW
- Analyst Count
- TYRA 7
- WIW 0
- Target Price
- TYRA $30.86
- WIW N/A
- AVG Volume (30 Days)
- TYRA 360.4K
- WIW 229.9K
- Earning Date
- TYRA 08-06-2025
- WIW 01-01-0001
- Dividend Yield
- TYRA N/A
- WIW 11.14%
- EPS Growth
- TYRA N/A
- WIW N/A
- EPS
- TYRA N/A
- WIW N/A
- Revenue
- TYRA N/A
- WIW N/A
- Revenue This Year
- TYRA N/A
- WIW N/A
- Revenue Next Year
- TYRA N/A
- WIW N/A
- P/E Ratio
- TYRA N/A
- WIW N/A
- Revenue Growth
- TYRA N/A
- WIW N/A
- 52 Week Low
- TYRA $6.42
- WIW $8.01
- 52 Week High
- TYRA $29.60
- WIW $9.37
- Technical
- Relative Strength Index (RSI)
- TYRA 41.84
- WIW 67.60
- Support Level
- TYRA $10.11
- WIW $8.54
- Resistance Level
- TYRA $10.68
- WIW $8.60
- Average True Range (ATR)
- TYRA 0.79
- WIW 0.06
- MACD
- TYRA -0.08
- WIW 0.02
- Stochastic Oscillator
- TYRA 7.05
- WIW 98.11
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.